- Home
- ISRL vs CSBR Comparison
ISRL vs CSBR Comparison
Compare ISRL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- CSBR
- Stock Information
- Founded
- ISRL 2021
- CSBR 1985
- Country
- ISRL United States
- CSBR United States
- Employees
- ISRL N/A
- CSBR N/A
- Industry
- ISRL Blank Checks
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISRL Finance
- CSBR Health Care
- Exchange
- ISRL Nasdaq
- CSBR Nasdaq
- Market Cap
- ISRL 80.2M
- CSBR 90.2M
- IPO Year
- ISRL 2023
- CSBR 1986
- Fundamental
- Price
- ISRL $12.40
- CSBR $6.44
- Analyst Decision
- ISRL
- CSBR Strong Buy
- Analyst Count
- ISRL 0
- CSBR 1
- Target Price
- ISRL N/A
- CSBR $12.00
- AVG Volume (30 Days)
- ISRL 8.1K
- CSBR 15.1K
- Earning Date
- ISRL 01-01-0001
- CSBR 09-15-2025
- Dividend Yield
- ISRL N/A
- CSBR N/A
- EPS Growth
- ISRL N/A
- CSBR N/A
- EPS
- ISRL 0.14
- CSBR 0.21
- Revenue
- ISRL N/A
- CSBR $56,878,000.00
- Revenue This Year
- ISRL N/A
- CSBR $7.31
- Revenue Next Year
- ISRL N/A
- CSBR $12.01
- P/E Ratio
- ISRL $91.33
- CSBR $30.28
- Revenue Growth
- ISRL N/A
- CSBR 10.11
- 52 Week Low
- ISRL $11.19
- CSBR $3.75
- 52 Week High
- ISRL $14.00
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- ISRL 48.55
- CSBR 46.75
- Support Level
- ISRL $12.09
- CSBR $6.29
- Resistance Level
- ISRL $12.35
- CSBR $6.79
- Average True Range (ATR)
- ISRL 0.19
- CSBR 0.25
- MACD
- ISRL -0.02
- CSBR 0.03
- Stochastic Oscillator
- ISRL 34.07
- CSBR 27.69
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.